NO20060398L - Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft - Google Patents

Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft

Info

Publication number
NO20060398L
NO20060398L NO20060398A NO20060398A NO20060398L NO 20060398 L NO20060398 L NO 20060398L NO 20060398 A NO20060398 A NO 20060398A NO 20060398 A NO20060398 A NO 20060398A NO 20060398 L NO20060398 L NO 20060398L
Authority
NO
Norway
Prior art keywords
cancer
inhibition
treatment
kinase inhibitor
combination
Prior art date
Application number
NO20060398A
Other languages
English (en)
Norwegian (no)
Inventor
Phillip Frost
Mary Carolyn Discafani-Marro
Lee Martin Greenberger
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20060398L publication Critical patent/NO20060398L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20060398A 2003-08-01 2006-01-25 Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft NO20060398L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49213203P 2003-08-01 2003-08-01
PCT/US2004/024478 WO2005018677A2 (en) 2003-08-01 2004-07-28 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer

Publications (1)

Publication Number Publication Date
NO20060398L true NO20060398L (no) 2006-02-28

Family

ID=34215843

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060398A NO20060398L (no) 2003-08-01 2006-01-25 Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft

Country Status (19)

Country Link
US (1) US20050026933A1 (pt)
EP (1) EP1648516A2 (pt)
JP (1) JP2007501238A (pt)
KR (1) KR20060054412A (pt)
CN (1) CN1832757A (pt)
AR (1) AR045179A1 (pt)
AU (1) AU2004266572A1 (pt)
BR (1) BRPI0413255A (pt)
CA (1) CA2533126A1 (pt)
CO (1) CO5640151A2 (pt)
CR (1) CR8181A (pt)
EC (1) ECSP066341A (pt)
IL (1) IL173081A0 (pt)
MX (1) MXPA06001110A (pt)
NO (1) NO20060398L (pt)
RU (1) RU2006106267A (pt)
TW (1) TW200515910A (pt)
WO (1) WO2005018677A2 (pt)
ZA (1) ZA200600915B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479466A1 (en) * 2002-03-29 2003-10-09 Exxonmobil Chemical Patents Inc. Oligomerization of olefins
EP1490314A1 (en) * 2002-03-29 2004-12-29 ExxonMobil Chemical Patents, Inc. a Corporation of the State of Delaware Preparation of alkylaromatic hydrocarbons and alkylaryl sulfonates
EP2439284B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
AU2005249200A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with oxaliplatin and an EGFR-inhibitor
WO2005117916A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
GB2427468B (en) 2005-04-05 2011-03-02 Cellpoint Diagnostics Cell separation device and method for the detection of EpCAM positive cells
AU2006236940A1 (en) * 2005-04-14 2006-10-26 Wyeth Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients
EP1906948A4 (en) * 2005-07-18 2010-03-17 Bipar Sciences Inc TREATMENT OF CANCER
ATE546148T1 (de) * 2005-07-21 2012-03-15 Nuvo Res Ag Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
JP2010503696A (ja) * 2006-09-13 2010-02-04 ヌベロ， インコーポレイテッド 癌を処置するための方法
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009064738A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
AU2008321382A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
AU2008333786A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) * 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
JP2012501654A (ja) * 2008-09-05 2012-01-26 アビラ セラピューティクス， インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
CN102713618B (zh) * 2009-09-16 2015-07-15 新基阿维罗米克斯研究公司 蛋白激酶复合物和抑制剂
EP2498751B1 (en) 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
WO2011082285A1 (en) 2009-12-30 2011-07-07 Avila Therapeutics, Inc. Ligand-directed covalent modification of protein
PL3089971T3 (pl) 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US12523663B2 (en) 2019-06-04 2026-01-13 Inserm (Institut National De La Santé Et De La Rescherche Médicale) Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US6821988B2 (en) * 2001-11-27 2004-11-23 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases

Also Published As

Publication number Publication date
BRPI0413255A (pt) 2006-10-03
ZA200600915B (en) 2007-12-27
AR045179A1 (es) 2005-10-19
CR8181A (es) 2006-07-14
AU2004266572A1 (en) 2005-03-03
TW200515910A (en) 2005-05-16
EP1648516A2 (en) 2006-04-26
US20050026933A1 (en) 2005-02-03
CA2533126A1 (en) 2005-03-03
JP2007501238A (ja) 2007-01-25
RU2006106267A (ru) 2006-07-27
MXPA06001110A (es) 2006-04-11
KR20060054412A (ko) 2006-05-22
CN1832757A (zh) 2006-09-13
WO2005018677A2 (en) 2005-03-03
WO2005018677A3 (en) 2006-05-26
CO5640151A2 (es) 2006-05-31
ECSP066341A (es) 2006-08-30
IL173081A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
MXPA06001110A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
ECSP055525A (es) Inhibidores de cinasas de tirosina
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
EA200801118A1 (ru) Способ ингибирования flt3 киназы
TNSN07212A1 (en) Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
EA200870454A1 (ru) Способ ингибирования c-kit киназы
ATE424208T1 (de) Proteinkinaseinhibitoren
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
WO2008036254A3 (en) Autophagic compounds and tyrosine kinase inhibitors for treating cancer
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application